CY1107617T1 - Σκευασμα που αποτελειται απο μεσυλικη (μεθανοσουλφονικη) φαιντολαμινη και η χρηση του - Google Patents

Σκευασμα που αποτελειται απο μεσυλικη (μεθανοσουλφονικη) φαιντολαμινη και η χρηση του

Info

Publication number
CY1107617T1
CY1107617T1 CY20071100532T CY071100532T CY1107617T1 CY 1107617 T1 CY1107617 T1 CY 1107617T1 CY 20071100532 T CY20071100532 T CY 20071100532T CY 071100532 T CY071100532 T CY 071100532T CY 1107617 T1 CY1107617 T1 CY 1107617T1
Authority
CY
Cyprus
Prior art keywords
adrenergic receptor
methanosulphone
fiendolamin
mesylic
alpha adrenergic
Prior art date
Application number
CY20071100532T
Other languages
English (en)
Inventor
Eckard Weber
Howard I Katz
Original Assignee
Novalar Pharmaceuticals, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novalar Pharmaceuticals, Inc filed Critical Novalar Pharmaceuticals, Inc
Publication of CY1107617T1 publication Critical patent/CY1107617T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Αποκαλύπτονται μέθοδοι αναστροφής της τοπικής αναισθησίας. Οι μέθοδοι περιλαμβάνουν τη χορήγηση ενός τοπικού αναισθητικού και (ενός) αγωνιστή του άλφα αδρενεργικού υποδοχέα για την επαγωγή τοπικής αναισθησίας ακολουθούμενη (η μέθοδος) από την αναστροφή της αναισθησίας με μια χαμηλή δόση ενός ανταγωνιστή του άλφα αδρενεργικού υποδοχέα. Επίσης αποκαλύπτονται τυποποιημένες συσκευασίες (kits) που περιέχουν ένα τοπικό αναισθητικό, ένα αγωνιστή του άλφα αδρενεργικού υποδοχέα και μια χαμηλή δόση ενός ανταγωνιστή του άλφα αδρενεργικού υποδοχέα.
CY20071100532T 2000-05-12 2007-04-19 Σκευασμα που αποτελειται απο μεσυλικη (μεθανοσουλφονικη) φαιντολαμινη και η χρηση του CY1107617T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20380000P 2000-05-12 2000-05-12
US23585500P 2000-09-27 2000-09-27
EP01933419A EP1280531B1 (en) 2000-05-12 2001-05-11 Formulation consisting of phentolamine mesylate and the use thereof

Publications (1)

Publication Number Publication Date
CY1107617T1 true CY1107617T1 (el) 2013-03-13

Family

ID=26898913

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100532T CY1107617T1 (el) 2000-05-12 2007-04-19 Σκευασμα που αποτελειται απο μεσυλικη (μεθανοσουλφονικη) φαιντολαμινη και η χρηση του

Country Status (14)

Country Link
US (8) US6432401B2 (el)
EP (2) EP1280531B1 (el)
JP (2) JP2003532678A (el)
AT (1) ATE352300T1 (el)
AU (3) AU2001259848B2 (el)
CA (1) CA2408417C (el)
CY (1) CY1107617T1 (el)
DE (1) DE60126265T2 (el)
DK (1) DK1280531T3 (el)
ES (1) ES2281418T3 (el)
NZ (1) NZ522930A (el)
PT (1) PT1280531E (el)
WO (1) WO2001085171A1 (el)
ZA (1) ZA200209811B (el)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE352300T1 (de) * 2000-05-12 2007-02-15 Novalar Pharmaceuticals Inc Zusammensetzung bestehend aus phentolaminmesylat und deren verwendung
CN100391460C (zh) * 2002-06-20 2008-06-04 诺瓦乐医药公司 α-肾上腺素能受体拮抗剂的稳定配方及其用途
BR0311965A (pt) 2002-06-20 2005-03-29 Novalar Pharmaceutical Inc Formulações estabilizadas de antagonistas de receptores alfa adrenérgicos e os seus usos
US7229630B2 (en) * 2002-06-20 2007-06-12 Novalar Pharmaceuticals, Inc. Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
US20030236306A1 (en) * 2002-06-20 2003-12-25 Chen Andrew X. Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
WO2008109124A1 (en) * 2007-03-06 2008-09-12 Novalar Pharmaceuticals, Inc. Use of nitroglycerin to reverse local anesthesia
CA2704928A1 (en) * 2007-11-06 2009-05-14 Stuart L. Weg Anesthetic composition, formulation and method of use
US20090131832A1 (en) * 2007-11-20 2009-05-21 Innovamedica S.A.P.I. De C.V. Electronic Syringe with Safety System for Spinal Injection
US8195287B2 (en) * 2007-12-05 2012-06-05 The Invention Science Fund I, Llc Method for electrical modulation of neural conduction
US8165669B2 (en) 2007-12-05 2012-04-24 The Invention Science Fund I, Llc System for magnetic modulation of neural conduction
US20090149799A1 (en) * 2007-12-05 2009-06-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for chemical modulation of neural activity
US8180447B2 (en) 2007-12-05 2012-05-15 The Invention Science Fund I, Llc Method for reversible chemical modulation of neural activity
US8170660B2 (en) 2007-12-05 2012-05-01 The Invention Science Fund I, Llc System for thermal modulation of neural activity
US8165668B2 (en) 2007-12-05 2012-04-24 The Invention Science Fund I, Llc Method for magnetic modulation of neural conduction
US8180446B2 (en) 2007-12-05 2012-05-15 The Invention Science Fund I, Llc Method and system for cyclical neural modulation based on activity state
US8170658B2 (en) 2007-12-05 2012-05-01 The Invention Science Fund I, Llc System for electrical modulation of neural conduction
US8989858B2 (en) 2007-12-05 2015-03-24 The Invention Science Fund I, Llc Implant system for chemical modulation of neural activity
US8523569B2 (en) * 2007-12-28 2013-09-03 Khashayar Kevin Neshat Controlled release local anesthetic for post dental surgery and method of use
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
EP2285402A2 (en) 2008-04-14 2011-02-23 Halozyme, Inc. Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
WO2010056622A1 (en) * 2008-11-11 2010-05-20 Targacept, Inc. TREATMENT WITH ALPHA α7-SELECTIVE LIGANDS
SE533552C2 (sv) * 2008-12-30 2010-10-26 Igeloesa Transplantation Science Ab Förfarande och lösning för behandling av en potentiell organdonator
US20110229451A2 (en) * 2009-03-06 2011-09-22 Halozyme, Inc. Temperature sensitive mutants of matrix metalloproteases and uses thereof
KR101453601B1 (ko) * 2009-05-29 2014-10-22 갈데르마 리써어치 앤드 디벨로프먼트 주입으로 인한 피부 반응 감소를 위한 필러와 아드레날린 수용체 작용제의 주사가능한 조합
WO2011001676A1 (ja) 2009-07-02 2011-01-06 国立大学法人山口大学 表面麻酔剤
FR2951450B1 (fr) 2009-10-20 2011-12-09 Commissariat Energie Atomique Peptides a proprietes d'antagoniste selectif des recepteurs adrenergiques alpha 2 et leurs applications
SE534862C2 (sv) 2010-05-14 2012-01-24 Vivoline Medical Ab Användning av en medicinsk vätska för behandling av ett uttaget organ
US8997136B2 (en) 2010-07-22 2015-03-31 Time Warner Cable Enterprises Llc Apparatus and methods for packetized content delivery over a bandwidth-efficient network
CN103140217B (zh) * 2010-08-06 2015-08-19 盖尔德马研究及发展公司 用于治疗或预防皮肤病的化合物的组合
WO2012031125A2 (en) 2010-09-01 2012-03-08 The General Hospital Corporation Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine
US9602414B2 (en) 2011-02-09 2017-03-21 Time Warner Cable Enterprises Llc Apparatus and methods for controlled bandwidth reclamation
WO2012122162A1 (en) * 2011-03-07 2012-09-13 3M Innovative Properties Company Microneedle devices and methods
US20150196625A9 (en) 2013-01-07 2015-07-16 Rudolph D. Paladini Metal Sensitive Mutants of Matrix Metalloproteases and uses thereof
ES2835398T3 (es) 2013-02-01 2021-06-22 Ocuphire Pharma Inc Métodos y composiciones para la administración oftálmica diaria de fentolamina para mejorar el rendimiento visual
ES2762153T3 (es) 2013-02-01 2020-05-22 Ocuphire Pharma Inc Soluciones oftálmicas acuosas de fentolamina y usos médicos de las mismas
WO2014152466A1 (en) * 2013-03-14 2014-09-25 Jsn I, Llc Taste masking of anesthetics and analgesics
US9393177B2 (en) 2013-08-20 2016-07-19 Anutra Medical, Inc. Cassette assembly for syringe fill system
WO2015103450A1 (en) * 2014-01-01 2015-07-09 Real Time Imaging Technologies, Llc Improved local anesthetic solution for dental and/or contrast media use
USD774182S1 (en) 2014-06-06 2016-12-13 Anutra Medical, Inc. Anesthetic delivery device
USD750768S1 (en) 2014-06-06 2016-03-01 Anutra Medical, Inc. Fluid administration syringe
USD763433S1 (en) 2014-06-06 2016-08-09 Anutra Medical, Inc. Delivery system cassette
WO2016115117A1 (en) 2015-01-12 2016-07-21 Real Time Imaging Technologies, Llc Low-dose x-ray imaging system
WO2018140894A1 (en) 2017-01-30 2018-08-02 Nevakar, Inc Norepinephrine compositions and methods therefor
WO2019226599A1 (en) * 2018-05-22 2019-11-28 Alkalidx, Inc. Diagnostics and treatments of anesthetic insensitive subjects
WO2020023084A1 (en) * 2018-07-26 2020-01-30 Applied Biology, Inc. Taar receptor agonists for the treatment of alopecia
EP3870170A4 (en) 2018-10-26 2022-07-20 Ocuphire Pharma, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF PRESBYOPIA, MYDRIASIS AND OTHER EYE DISEASES
CN110193011B (zh) * 2019-06-19 2022-02-11 四川美大康华康药业有限公司 一种甲磺酸酚妥拉明注射液及其制备方法
CN115368310A (zh) 2021-05-18 2022-11-22 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3919425A (en) * 1971-04-09 1975-11-11 Miles Lab Method of producing vasodilation using certain 3-substituted-quinazoline derivatives
IL53452A (en) * 1976-11-30 1980-12-31 Pierpaoli W Combination of drugs for the selective control of immune reactions
US4197301A (en) * 1978-10-16 1980-04-08 Allergan Pharmaceuticals, Inc. Topical ophthalmic use of Prazosin
US4508715A (en) * 1981-07-01 1985-04-02 University Of Georgia Research Foundation, Inc. Antagonism of central nervous system drugs by the administration of 4-aminopyridine alone or in combination with other drugs
SU1082432A1 (ru) * 1981-07-02 1984-03-30 Горьковский государственный медицинский институт им.С.М.Кирова Способ лечени сосудистых заболеваний мозга
ATE19203T1 (de) * 1981-11-12 1986-05-15 John Joseph Jacklich Zahnspritze.
US4659714A (en) * 1984-03-27 1987-04-21 Dentsply, Ltd. Anesthetic methods for mammals
DK193287A (da) 1986-04-16 1987-10-17 Alcan Int Ltd Sammensat membran
IE60588B1 (en) * 1986-07-30 1994-07-27 Sumitomo Pharma Carbapenem compound in crystalline form, and its production and use
US4938970A (en) 1987-02-06 1990-07-03 Hustead Robert E Painless electrolyte solutions
US5149320A (en) * 1988-04-11 1992-09-22 Dhaliwal Avtar S Composite anesthetic article and method of use
US5261903A (en) * 1988-04-11 1993-11-16 M.D. Inc. Composite anesthetic article and method of use
JP2824863B2 (ja) * 1989-07-12 1998-11-18 エーザイ株式会社 α▲下１▼―ブロッカー点眼剤
US5236904A (en) * 1989-09-18 1993-08-17 Senetek, Plc Erection-inducing methods and compositions
US5447912A (en) * 1989-09-18 1995-09-05 Senetek, Plc Erection-inducing methods and compositions
DE69105040T2 (de) * 1990-05-31 1995-03-23 Pfizer, Inc., New York, N.Y. Arzneimittel gegen Impotenz.
US5192527A (en) * 1991-07-01 1993-03-09 Abrahmsohn Glenn M Method of reversing local anesthesia and reagent system therefor
US6291528B1 (en) * 1991-07-03 2001-09-18 Nathan Earl Scott Prostaglandin E1/F2 in combination with prostaglandin F2α for enhancing female sexual arousal
US5370613A (en) * 1993-02-11 1994-12-06 Helmy; Ali M. Catheter apparatus for delivering drugs to the penis
US5635204A (en) * 1994-03-04 1997-06-03 Montefiore Medical Center Method for transdermal induction of anesthesia, analgesia or sedation
JPH07258068A (ja) * 1994-03-18 1995-10-09 Kao Corp 浴用剤組成物
US5731339A (en) * 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
WO1999002147A1 (en) * 1997-07-09 1999-01-21 Androsolutions, Inc. Improved methods and compositions for treating male erectile dysfunction
CN1282249A (zh) * 1997-12-18 2001-01-31 内森·厄尔·斯科特 用于治疗阳痿和增强性唤起的前列腺素E2/F2α组合剂
NZ506596A (en) 1998-02-27 2003-10-31 Synchroneuron Llc Compositions comprising an alpha1-adrenergic antagonist, sucralfate and a local anaesthetic and further comprising nitroglycerin
JPH11282142A (ja) * 1998-03-30 1999-10-15 Fuji Photo Film Co Ltd 感光材料処理装置の処理部密閉構造
US6001845A (en) * 1998-06-19 1999-12-14 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
US6482426B1 (en) * 1998-09-17 2002-11-19 Zonagen, Inc. Compositions for the treatment of male erectile dysfunction
US6416323B1 (en) * 2000-05-11 2002-07-09 Safety Syringes, Inc. Aspirating dental syringe with needle shield
ATE352300T1 (de) 2000-05-12 2007-02-15 Novalar Pharmaceuticals Inc Zusammensetzung bestehend aus phentolaminmesylat und deren verwendung

Also Published As

Publication number Publication date
DE60126265D1 (de) 2007-03-15
US20090076023A1 (en) 2009-03-19
EP1762236B1 (en) 2015-07-15
AU5984801A (en) 2001-11-20
DE60126265T2 (de) 2007-10-31
EP1762236A2 (en) 2007-03-14
EP1280531B1 (en) 2007-01-24
JP2006225400A (ja) 2006-08-31
US20020183396A1 (en) 2002-12-05
ZA200209811B (en) 2003-12-03
CA2408417A1 (en) 2001-11-15
AU2001259848B2 (en) 2005-10-13
WO2001085171A1 (en) 2001-11-15
ES2281418T3 (es) 2007-10-01
AU2005211689B2 (en) 2008-02-21
US7261889B2 (en) 2007-08-28
US20050165097A1 (en) 2005-07-28
US20010056125A1 (en) 2001-12-27
US20040063747A1 (en) 2004-04-01
US20020183356A1 (en) 2002-12-05
CA2408417C (en) 2009-09-15
JP2003532678A (ja) 2003-11-05
NZ522930A (en) 2004-10-29
US6432401B2 (en) 2002-08-13
US20040198816A1 (en) 2004-10-07
EP1280531A1 (en) 2003-02-05
PT1280531E (pt) 2007-02-28
US6872390B2 (en) 2005-03-29
ATE352300T1 (de) 2007-02-15
US6764678B2 (en) 2004-07-20
DK1280531T3 (da) 2007-05-29
EP1762236A3 (en) 2007-10-31
EP1280531A4 (en) 2005-05-11
US20050165098A1 (en) 2005-07-28
AU2005211689A1 (en) 2005-10-13

Similar Documents

Publication Publication Date Title
CY1107617T1 (el) Σκευασμα που αποτελειται απο μεσυλικη (μεθανοσουλφονικη) φαιντολαμινη και η χρηση του
UY27760A1 (es) Nuevos derivados de pirrolidinio.
EA200300026A1 (ru) Аналоги глюкагоноподобного пептида-1
DE60008374D1 (de) Anästhetische zubereitung enthaltend einen nmda-antagonisten und einen alpha-2 adrenergen agonisten
CY1105227T1 (el) Ενωσεις πιπepιδινης ως αντιαλλepγικα
PL357944A1 (en) Intradermal-penetration agents for topical local anesthetic administration
DE602004026113D1 (de) Glp-1-verbindungen
BRPI0408247A (pt) usos de antagonistas e agonistas de il-23 e reagentes relacionados
EA200300717A1 (ru) Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
RS50273B (sr) Antagonisti receptora epidermalnog faktora rasta za lečenje hipersekrecije mukusa u plućima
CY1105721T1 (el) Δερματικοι αναισθητικοι παραγοντες
NO960630L (no) Heterocykler anvendelige som neurokinin antagonister
PT1506185E (pt) Compostos novos e sua utilizacao
BR0315644A (pt) Piperazinil e diazapanil benzamidas e benzotioamidas
ES2190205T3 (es) Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda.
RS50768B (sr) Režim doziranja i farmaceutska formulacija za urgentnu zaštitu
ATE300543T1 (de) Kondensierte pyrazindionderivate als pde5 inhibitore
BR9909486A (pt) Compostos calcilìticos
BR0314844A (pt) Novo composto
BR0314843A (pt) Novo composto
DE60112960D1 (de) Kondensierte pyridoindolderivate
NO922380L (no) Substituerte 4-fenyl-4-piperidinkarboksamider med baade lokal anestetisk og analgetisk effekt samt fremgangsmaater for deres fremstilling
DE60141297D1 (de) Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper
BR0317623A (pt) Escitalopram, composição farmacêutica, e, uso de hidrobrometo de escitalopram
BR0308874A (pt) Composição aquosa injetável, método para produzir a mesma, e, uso de copolìmeros em bloco polioxipropileno/polioxietileno